Targeting to cancer relies on differences between healthy cells and cancerous ones. For example, differences in mucin 16 can be used as a target moiety for drug delivery. Researchers at University of Portugal used PLGA-PEG-Mal (Cat# AI110) and PLGA-FKR648 (Cat# AV015) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create nanoparticles with mucin-based targeting for cancer therapy. This research holds promise to improve cancer treatments in the future. Read more: Freitas, Rui, Eduardo Ferreira, Andreia Miranda, Dylan Ferreira, Marta Relvas-Santos, Flávia Castro, Beatriz Santos et al. "Targeted and Self-Adjuvated Nanoglycovaccine Candidate for Cancer Immunotherapy." ACS nano 18, no. 14 (2024): 10088-10103. https://pubs.acs.org/doi/abs/10.1021/acsnano.3c12487
“Advanced-stage solid primary tumors and metastases often express mucin 16 (MUC16), carrying immature glycans such as the Tn antigen, resulting in specific glycoproteoforms not found in healthy human tissues. This presents a valuable approach for designing targeted therapeutics, including cancer glycovaccines, which could potentially promote antigen recognition and foster the immune response to control disease spread and prevent relapse. In this study, we describe an adjuvant-free poly(lactic-co-glycolic acid) (PLGA)-based nanoglycoantigen delivery approach that outperforms conventional methods by eliminating the need for protein carriers while exhibiting targeted and adjuvant properties. To achieve this, we synthesized a library of MUC16-Tn glycoepitopes through single-pot enzymatic glycosylation, which were then stably engrafted onto the surface of PLGA nanoparticles, generating multivalent constructs that better represent cancer molecular heterogeneity. These glycoconstructs demonstrated affinity for Macrophage Galactose-type Lectin (MGL) receptor, known to be highly expressed by immature antigen-presenting cells, enabling precise targeting of immune cells. Moreover, the glycopeptide-grafted nanovaccine candidate displayed minimal cytotoxicity and induced the activation of dendritic cells in vitro, even in the absence of an adjuvant. In vivo, the formulated nanovaccine candidate was also nontoxic and elicited the production of IgG specifically targeting MUC16 and MUC16-Tn glycoproteoforms in cancer cells and tumors, offering potential for precise cancer targeting, including targeted immunotherapies. KEYWORDS: glycovaccines nanovaccines cancer immunotherapy cancer glycosylation glycoantigens glycoconjugates”
PLGA-PEG-Mal (Cat# AI110): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AI110#h
PLGA-FKR648 (Cat# AV015): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AV015#h
NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/
NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/
No comments:
Post a Comment